Table 2.
ΔTILs among patients with different clinicopathological characteristics
| Characteristic | ΔTILs (%) |
p-value | |
|---|---|---|---|
| Median (IQR) | Mean±SD | ||
| Age (yr) | |||
| < 60 | 2.0 (0.0-17.0) | 11.1±19.6 | 0.016 |
| ≥ 60 | 0.0 (0.0-5.0) | 4.9±13.3 | |
| Menstrual status | |||
| Premenopausal | 0.0 (0.0-15.0) | 11.2±20.5 | 0.888 |
| Postmenopausal | 1.0 (0.0-10.0) | 7.24±15.8 | |
| Tumor size (cm) | |||
| ≤ 2 | 0.0 (0.0-10.0) | 8.0±17.8 | 0.517 |
| > 2 | 1.0 (0.0-12.0) | 9.0±17.5 | |
| Axillary lymph node status | |||
| Negative | 0.0 (0.0-10.0) | 8.7±17.3 | 0.973 |
| Positive | 1.0 (0.0-12.0) | 8.4±18.0 | |
| Histological grade | |||
| I-II | 0.0 (0.0-10.0) | 7.2±15.3 | 0.360 |
| III | 2.0 (0.0-20.0) | 10.4±20.5 | |
| NA | 2.0 (0.0-12.5) | 7.2±11.7 | |
| ER | |||
| Negative | 6.0 (0.0-30.0) | 15.3±24.5 | 0.006 |
| Positive | 0.0 (0.0-7.0) | 6.2±13.7 | |
| PR | |||
| Negative | 2.0 (0.0-17.0) | 10.5±20.0 | 0.110 |
| Positive | 0.0 (0.0-10.0) | 7.4±16.0 | |
| HER2 | |||
| Negative | 1.0 (0.0-10.0) | 7.5±15.2 | 0.602 |
| Positive | 0.0 (0.0-27.5) | 13.0±24.7 | |
| Ki67 (%) | |||
| < 20 | 0.0 (0.0-5.0) | 4.8±11.5 | 0.062 |
| ≥ 20 | 2.0 (0.0-15.0) | 10.5±19.8 | |
| Molecular subtype | |||
| Luminal A | 2.0 (0.0-13.0) | 6.8±11.7 | 0.074 |
| Luminal B-HER2– | 0.0 (0.0-7.0) | 6.1±13.4 | |
| Luminal B-HER2+ | 0.0 (0.0-14.5) | 8.3±21.2 | |
| HER2 positive | 8.5 (0.0-38.5) | 17.5±27.4 | |
| Triple negative | 5.0 (0.0-20.5) | 13.0±21.7 | |
| Surgery time interval (day) | |||
| < 4 | 0.0 (0.0-5.0) | 4.9±15.4 | 0.003 |
| ≥ 4 | 2.0 (0.0-16.0) | 11.1±18.6 | |
Pathological data is based on surgery removed sample. p-value calculated by Mann-Whitney U test. TILs, tumor infiltrating lymphocytes; IQR, interquartile range; SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.